Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
48.00    3.50 (7.87%)
Bid:
47.50
Ask:
48.50
Spread: 1.00 (2.105%)
Market Cap: £92.09m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Corporate Update

18 Jan 2016 07:00

RNS Number : 1092M
Iofina PLC
18 January 2016
 

 

18 January 2016

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Corporate Update

Annualised iodine production increase of over 73%

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, today provides an update to the market regarding record crystalline iodine production totals in 2015.

 

During the period, Iofina produced a total of 569.1 metric tonnes ("MT") of crystalline iodine (2014: 327.7MT) from its IOsorb® plants. Although the Company experienced power outages at its IOsorb® plants and at its partners' operations due to adverse weather conditions in late December, resulting in a loss of anticipated production of about 5-7MT of crystalline iodine in the month, the Board is pleased with the like-for-like increase of over 73% of crystalline iodine from our IOsorb® facilities in its core area in Oklahoma.

 

As previously stated, restrictions of particular Salt Water Disposal wells ("SWD") due to seismic activity has marginally impacted the Company's total brine supply. The Company is developing alternatives to mitigate risk associated with potential future restrictions of individual SWDs. The Board's aim is to not only limit risk exposure, but increase the available brine supply to Iofina's IOsorb® plants. Iofina is working with its partners on strategic plans to reduce risk and potentially expand brine supply and the Board looks forward to updating the market in due course.

 

Under current operating conditions, Iofina expects to produce 250-270MT of crystalline iodine in H1 2016 from its five existing IOsorb® plants. This production estimated range is based on the current injection restrictions at certain sites. Again, the Company is working closely with its partners to mitigate and possibly eliminate these flow restrictions.

 

Iofina continues to consume a large amount of its produced iodine through its halogen derivatives division, Iofina Chemical ("IC"). Iodine use at IC was at record levels for the Company in 2015. The Company is encouraged to report that it has successfully marketed and sold significant quantities of IOsorb® produced iodine into the global market place. In line with other commodities in the global market, the price for iodine has continued to soften. Iodine worldwide is generally sold in US Dollars. The strengthening of the US Dollar versus other global currencies has further impacted iodine pricing.

 

In order to manage the impact of these extraneous fluctuations, the Company has successfully cut expenses, reduced production and corporate costs and continues to investigate additional cost cutting measures. These measures are expected to protect the Company's cash position and have a positive impact on the Company's gross margins for the current financial year as it moves toward cashflow positive operations.

 

 

 

 

Commenting, President and CEO Dr. Tom Becker, stated: 

 

"While the Board is encouraged by the sizeable year-on-year iodine production increase and overall operational gains, with the backdrop of an uncertain capital markets and commodity climate, 2016 will be a year of prudency and value protection. The Company remains focused on seeking out ways to streamline efficiencies and mitigate risk, while expanding production at its current plants and future operations." 

 

 

For further information, please contact:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Joanna Scott

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Dominic Barretto/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7768 537 739

About Iofina:

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBIGDBCGBBGLR
Date   Source Headline
20th May 20197:00 amRNSProposed Placing and Open Offer
14th May 20197:00 amRNSStatement regarding share price rise
1st May 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSQ1 2019 Market Update
1st Apr 20197:00 amRNSCompletion of Debt Restructuring
22nd Feb 20194:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:35 pmRNSPrice Monitoring Extension
12th Feb 20197:00 amRNSDebt Restructuring
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
22nd Jan 20197:00 amRNSChange of Registered Office
17th Jan 20197:00 amRNSMarket Update
20th Nov 20184:40 pmRNSSecond Price Monitoring Extn
20th Nov 20184:35 pmRNSPrice Monitoring Extension
16th Nov 20187:00 amRNSDirector Appointment
18th Oct 20184:40 pmRNSSecond Price Monitoring Extn
18th Oct 20184:35 pmRNSPrice Monitoring Extension
10th Oct 20187:00 amRNSQ3 2018 Update
20th Sep 20187:00 amRNSInterim Results
16th Jul 20187:00 amRNSH1 2018 Update
18th Jun 20187:00 amRNSMarket update
14th Jun 20187:00 amRNSGrant of Options
13th Jun 201811:30 amRNSResult of AGM
30th Apr 20187:00 amRNSFinal Results and Notice of AGM
18th Apr 20187:00 amRNSQ1 2018 Market Update
16th Apr 20181:30 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
20th Mar 20183:05 pmRNSHolding(s) in Company
15th Mar 20181:24 pmRNSHolding(s) in Company
14th Feb 20187:00 amRNSProduction commences at IO#7
30th Jan 20183:00 pmRNSHolding(s) in Company
15th Jan 20187:00 amRNSMarket Update
14th Dec 20177:00 amRNSMarket Update
16th Nov 20177:00 amRNSIO#7 Progress and Market Update
20th Oct 20174:40 pmRNSSecond Price Monitoring Extn
20th Oct 20174:35 pmRNSPrice Monitoring Extension
10th Oct 20177:00 amRNSQ3 2017 Market Update
22nd Sep 20177:00 amRNSInterim Results
12th Sep 20177:00 amRNSConstruction of IO#7 to Expand Iodine Production
14th Jul 20177:00 amRNSCorporate and Production Update
14th Jun 201712:15 pmRNSResult of AGM
13th Jun 201712:07 pmRNSSecond Price Monitoring Extn
13th Jun 201712:02 pmRNSPrice Monitoring Extension
8th Jun 201712:07 pmRNSSecond Price Monitoring Extn
8th Jun 201712:02 pmRNSPrice Monitoring Extension
7th Jun 201712:07 pmRNSSecond Price Monitoring Extn
7th Jun 201712:02 pmRNSPrice Monitoring Extension
6th Jun 201712:07 pmRNSSecond Price Monitoring Extn
6th Jun 201712:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.